液体活检与肿瘤标志物诊断早期肝细胞癌的研究进展  

Liquid biopsy and tumor markers in early diagnosis of hepatocellular carcinoma

作　　者：杜逸玮 贾军梅[2] 王兴 DU Yiwei;JIA Junmei;WANG Xing(the First Clinical Medical College of Shanxi Medical University,Taiyuan,Shanri 03000l,China;Department of Oncology,the First Hospital of Shanxi Medical University,Taiyuan,Shanri 03000l,China)

机构地区：[1]山西医科大学第一临床医学院,山西太原030001 [2]山西医科大学第一医院肿瘤科,山西太原030001

出　　处：《中华实用诊断与治疗杂志》2023年第7期689-693,共5页Journal of Chinese Practical Diagnosis and Therapy

基　　金：山西省卫生健康委员会科研计划项目(2022013)。

摘　　要：肝细胞癌(HCC)是临床常见的恶性肿瘤之一,晚期患者无手术治疗机会,生存期短,预后差。肝组织穿刺活检病理检查是术前诊断HCC的金标准,但其为侵袭性检查,无法动态监测病情的进展。甲胎蛋白是临床早期诊断HCC的指标之一,但特异度、灵敏度较低。甲胎蛋白异质体、维生素K缺乏或拮抗剂Ⅱ诱导蛋白等是近年发现的诊断HCC的肿瘤标志物,有较高的特异度,可提高HCC早期诊断率。液体活检是一种非侵入性诊断技术,通过分析体液样本如血液、尿液、脑脊液等中的生物标志物来诊断及评估疾病,对HCC的早期诊断、疾病进展评估和治疗方案的制订有重要意义。本文就液体活检联合肿瘤标志物检测在HCC早期诊断应用中的研究进展作一综述。Hepatocellular carcinoma(HCC) is one of the common malignant tumors,characterized by no treatment options,poor prognosis,and short overall survival.Although the liver tissue biopsy histopathologic result is regarded as the gold standard for preoperative diagnosis of HCC,liver tissue biopsy is an invasive procedure and cannot dynamically monitor the disease progression.Alpha-fetoprotein is one of the indexes of early diagnosis of HCC,but its sensitivity and specificity are low.HCC-specific markers such as lens culinaris agglutinin-reactive fraction of AFP and protein induced by vitamin K absence or antagonist-Ⅱ have high specificities and can improve the early diagnostic rate of HCC.Liquid biopsy is a non-invasive diagnostic technique and it diagnoses and evaluates diseases by analyzing biomarkers in body fluid samples such as blood,urine,and cerebrospinal fluid.It holds potential clinical applications in the early diagnosis,evaluation of disease development and formulating treatment protocol of HCC.This paper reviews the research progress of the application of liquid biopsy combined with tumor marker detection in the early diagnosis of HCC.

关 键 词：肝细胞癌 液体活检 肿瘤标志物 甲胎蛋白异质体 维生素K缺乏或拮抗剂Ⅱ诱导蛋白 

分 类 号：R735.7[医药卫生—肿瘤]